Actively Recruiting
A Study of Ivonescimab in People With Endometrial and Cervical Cancers
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-03-25
50
Participants Needed
7
Research Sites
104 weeks
Total Duration
On this page
Sponsors
M
Memorial Sloan Kettering Cancer Center
Lead Sponsor
S
Summit Therapeutics
Collaborating Sponsor
AI-Summary
What this Trial Is About
The researchers are doing this study to find out if ivonescimab is an effective treatment for people with endometrial cancer (EC) and/or cervical cancer (CC). The researchers will also look at whether the study drug is safe and causes few or mild side effects in participants.
CONDITIONS
Official Title
A Study of Ivonescimab in People With Endometrial and Cervical Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female patients aged 18 years or older
- Histologically confirmed metastatic or recurrent endometrial or cervical cancer progressed after at least one platinum-based regimen
- Specific histologies allowed for endometrial and cervical cancers as defined
- Measurable disease per RECIST v1.1 criteria
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2
- Adequately controlled blood pressure (≤160/90 mmHg) with or without medication
- Adequate hematologic, renal, hepatic, and coagulation laboratory values as specified
- Patients with treated brain metastases allowed if no progression, no bleeding risk, and off corticosteroids
- Not pregnant and not nursing; negative pregnancy test if of childbearing potential
- Female patients of childbearing potential must agree to use highly effective contraception from screening until 90 days after last dose
- Clinical IMPACT data available or adequate tissue for testing
- Prior or concurrent malignancies allowed if not interfering with study assessments
You will not qualify if you...
- Major surgery or serious trauma within 4 weeks before enrollment or planned within 4 weeks after first dose
- Not recovered from surgery-related toxicity before starting therapy
- History of bleeding tendencies, significant bleeding symptoms, or coagulopathy within 4 weeks
- Need for new therapeutic anticoagulant therapy within 14 days prior to enrollment
- Unstable angina, myocardial infarction, congestive heart failure (NYHA grade ≥2), or vascular disease requiring hospitalization within 12 months
- History of severe gastrointestinal conditions or bleeding within 6 months
- Recent arterial or venous thromboembolic events or cerebrovascular events within 6 months
- Acute exacerbation of chronic obstructive pulmonary disease within 4 weeks
- History of gastrointestinal perforation, obstruction, or extensive bowel surgery within 6 months
- Imaging showing major blood vessel invasion or tumor cavitation
- Recent participation in another cancer investigational study within 4 weeks
- Prolonged QTc interval >480 msec
- Active or acute Hepatitis B or C infection not controlled
- Known intolerance to study drugs or excipients
- History of organ transplant
- Immunodeficiency or systemic immunosuppressive therapy within 7 days prior to first dose
- Active autoimmune disease requiring systemic treatment in past 2 years
- History of pneumonitis requiring steroids or current pneumonitis
- Prior immune-related adverse events Grade 3 or higher causing immunotherapy delay or discontinuation
- Live-virus vaccination within 30 days prior to treatment start
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Basking Ridge, New Jersey, United States, 07920
Actively Recruiting
2
Memorial Sloan Kettering Monmouth (All Protocol Activities)
Middletown, New Jersey, United States, 07748
Actively Recruiting
3
Memorial Sloan Kettering Bergen (All Protocol Activities)
Montvale, New Jersey, United States, 07645
Actively Recruiting
4
Memorial Sloan Kettering Suffolk- Commack (All Protocol Activities)
Commack, New York, United States, 11725
Actively Recruiting
5
Memorial Sloan Kettering Westchester (All Protocol Activities)
Harrison, New York, United States, 10604
Actively Recruiting
6
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, United States, 10065
Actively Recruiting
7
Memorial Sloan Kettering Nassau (All Protocol Activities)
Uniondale, New York, United States, 11553
Actively Recruiting
Research Team
M
Maria Rubinstein, MD
CONTACT
V
Vicky Makker, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here